Patents by Inventor Wrickban MAZUMDAR

Wrickban MAZUMDAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
    Patent number: 12030901
    Abstract: Disclosed herein are compounds that can act as inhibitors of nicotinamide phosphoribosyltransferase (“NAMPT”), and methods for their use in treating or preventing diseases, such as pulmonary arterial hypertension (“PAH”). The compounds described herein can include compounds of Formula (II) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: July 9, 2024
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, The Board of Trustees of the University of Illinois
    Inventors: Tom G. Driver, Roberto F. Machado, Naijing Su, Xinyu Guan, Wrickban Mazumdar, Kira Ratia, Jason Ralph Hickok, Angelia Denise Lockett
  • PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20240150318
    Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.
    Type: Application
    Filed: June 12, 2023
    Publication date: May 9, 2024
    Inventors: Arnab K. Chatterjee, Jian Jeffrey Chen, Elshan Nakath, Alireza Rahimi, Anil Kumar Gupta, Gennadii Grabovyi, Katy Wilson, Sourav Ghorai, Armen Nazarian, James Pedroarena, Wrickban Mazumdar, Frank Weiss, Lirui Song, Malina A. Bakowski, Laura Riva, Karen Wolff, Case W. McNamara, Thomas F. Rogers, Jacqueline Malvin, Shuangwei Li, Sean Joseph, Ashley Woods, Yuyin Liu, Neechi Okwor
  • Protease inhibitors for treatment of coronavirus infections
    Patent number: 11708348
    Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: July 25, 2023
    Assignee: The Scripps Research Institute
    Inventors: Arnab K. Chatterjee, Jian Jeffrey Chen, Elshan Nakath, Alireza Rahimi, Anil Kumar Gupta, Gennadii Grabovyi, Katy Wilson, Sourav Ghorai, Armen Nazarian, James Pedroarena, Wrickban Mazumdar, Frank Weiss, Lirui Song, Malina A. Bakowski, Laura Riva, Karen Wolff, Case W. McNamara, Thomas F. Rogers, Jacqueline Malvin, Shuangwei Li, Sean Joseph, Ashley Woods, Yuyin Liu, Neechi Okwor
  • NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME
    Publication number: 20230124268
    Abstract: Disclosed herein are compounds that can act as inhibitors of nicotinamide phosphoribosyltransferase (“NAMPT”), and methods for their use in treating or preventing diseases, such as pulmonary arterial hypertension (“PAH”). The compounds described herein can include compounds of Formula (II) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Application
    Filed: November 16, 2022
    Publication date: April 20, 2023
    Inventors: Tom G. DRIVER, Roberto F. MACHADO, Najing SU, Xinyu GUAN, Wrickban MAZUMDAR, Kira RATIA, Jason Ralph HICKOK, Angelia Denise LOCKETT
  • Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
    Patent number: 11584766
    Abstract: Disclosed herein are compounds that can act as inhibitors of nicotinamide phosphoribosyltransferase (“NAMPT”), and methods for their use in treating or preventing diseases, such as pulmonary arterial hypertension (“PAH”). The compounds described herein can include compounds of Formula (II) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: February 21, 2023
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tom G. Driver, Roberto F. Machado, Najing Su, Xinyu Guan, Wrickban Mazumdar, Kira Ratia, Jason Ralph Hickok, Angelia Denise Lockett
  • Protease Inhibitors for Treatment of Coronavirus Infections
    Publication number: 20230033285
    Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.
    Type: Application
    Filed: June 16, 2022
    Publication date: February 2, 2023
    Inventors: Arnab K. Chatterjee, Jian Jeffrey Chen, Elshan Nakath, Alireza Rahimi, Anil Kumar Gupta, Gennadii Grabovyi, Katy Wilson, Sourav Ghorai, Armen Nazarian, James Pedroarena, Wrickban Mazumdar, Frank Weiss, Lirui Song, Malina A. Bakowski, Laura Riva, Karen Wolff, Case W. McNamara, Thomas F. Rogers, Jacqueline Malvin, Shuangwei Li, Sean Joseph, Ashley Woods, Yuyin Liu, Neechi Okwor
  • Protease Inhibitors for Treatment of Coronavirus Infections
    Publication number: 20230024012
    Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.
    Type: Application
    Filed: June 10, 2022
    Publication date: January 26, 2023
    Inventors: Arnab K. Chatterjee, Jian Jeffrey Chen, Elshan Nakath, Alireza Rahimi, Anil Kumar Gupta, Gennadii Grabovyi, Katy Wilson, Sourav Ghorai, Armen Nazarian, James Pedroarena, Wrickban Mazumdar, Frank Weiss, Lirui Song, Malina A. Bakowski, Laura Riva, Karen Wolff, Case W. McNamara, Thomas F. Rogers, Jacqueline Malvin, Shuangwei Li, Sean Joseph, Ashley Woods, Yuyin Liu, Neechi Okwor
  • NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME
    Publication number: 20210070784
    Abstract: Disclosed herein are compounds that can act as inhibitors of nicotinamide phosphoribosyltransferase (“NAMPT”), and methods for their use in treating or preventing diseases, such as pulmonary arterial hypertension (“PAH”). The compounds described herein can include compounds of Formula (II) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Application
    Filed: February 5, 2019
    Publication date: March 11, 2021
    Inventors: Tom G. DRIVER, Roberto F. MACHADO, Najing SU, Xinyu GUAN, Wrickban MAZUMDAR, Kira RATIA, Jason Ralph HICKOK, Angelia Denise LOCKETT